Pharmaceutical development for transdermal dosage forms of nifedipine: justification of the choice and specificity of the action

Author:

Tokaev V. V.1ORCID,Stepanova E. F.1ORCID,Makieva M. S.2ORCID,Morozov Yu. A.2ORCID,Pozdnyakov D. I.1ORCID,Gagloeva D. I.2ORCID

Affiliation:

1. Pyatigorsk Medical and Pharmaceutical Institute – Branch of the Volga State Medical University of the Ministry of Health of Russia

2. K.L. Khetagurov North Ossetian State University

Abstract

Background. Present day in medicine can be assessed as an active period of the fight against cardiovascular diseases. This group of diseases cannot be considered obsolete in any way, and even taking into account the emerging new pathology – coronavirus infection – cardiovascular diseases have consolidated their dominant position. Among the drugs used for appropriate pharmacotherapy, stands out nifedipine (1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridindicarboxylic acid dimethyl ether) – a drug that can inhibit the flow of calcium into the cardiomyocytes of vascular smooth muscle cells. The drug has been on the domestic pharmaceutical market for quite a long time, but it is still in demand. However, nifedipine has quite pronounced side effects, including those associated with its oral administration – nausea caused by irritation of the gastrointestinal tract, rarely gum hyperplasia. And at the same time, the main modern dosage form of nifedipine is tablets. Therefore, expanding the range of its dosage forms is an urgent issue. Moreover, well-chosen dosage forms reduce the side effect of the drug. This is especially true for extended versions. So pharmaceutical development in relation to the creation of original dosage forms of nifedipine is quite appropriate.Aim. Determination of the possibility of absorption of nifedipine from the proposed dosage forms – transdermal patch and transdermal gel.Materials and methods. To determine nifedipine in rat blood plasma samples, high-performance liquid chromatography was used (chromatograph “Millichrome A-02” (Institute of Chromatography “EcoNova”, LLC, Russia).Results. Chromatograms of blood plasma samples of all animals on whose skin a transdermal gel or patch was applied revealed a peak coinciding in retention time with the peak of the standard sample of nifedipine.Conclusion. The possibility of penetration of nifedipine from the patch and transdermal gel through intact animal skin has been confirmed.

Publisher

Publishing House ABV Press

Subject

General Medicine

Reference10 articles.

1. Zaslavskaya R.M., Veklenko G.V., Teiblum M.M. Chronosensitivity to cordipine (nifedipine) in patients with angina. The scientific heritage 2022;2(84):22–4. (In Russ.). DOI: 10.24412/9215-0365-2022-84-2-22-24

2. Abritsova M.V., Torchua N.R., Bogdanova E.M., Markina M.A. Non-surgical treatment of chronic anal fissure. Ambulatornaya khirurgiya = Outpatient Surgery 2022;19(1):90–6. (In Russ.). DOI: 10.21518/1995-1477-2022-19-1-90-6

3. Rodina T.A., Melnikov E.S., Belkov S.A. et al. Therapeutic drug monitoring of nifedipine by HPLC-MS/MS in the treatment of arterial hypertension. Biomedicina = Biomedicine 2017;(3):53–69 (In Russ.).

4. Melnikov, E.S., Belova M.V., Rodina T.A., Ramenskaya G.V. Determination of certain antihypertensive drugs in blood plasma by high–performance liquid chromatography/tandem mass spectrometry in the analysis of acute poisoning. Sorbtsionnye i khromatograficheskie processy = Sorption and Chromatographic Processes 2015;(15-2):257–68. (In Russ.). DOI: 10.17308/sorpchrom.2015.15/274

5. Podorozhnaya M.G., Gladukh E.V. Development of the compo sition and technology of wound healing action. Norwegian journal of development of the international science 2018;(8):54–8. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3